Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$61.27

-2.16 (-3.41%)

, AGN

Allergan

$216.81

-4.44 (-2.01%)

15:32
01/11/17
01/11
15:32
01/11/17
15:32

AbbVie promises to keep drug price increases under 10%, Reuters reports

AbbVie (ABBV) CEO Richard Gonzalez promised to keep all drug price increases in 2017 under 10%, following Allergan (AGN) and Novo Nordisk's (NVO) pledge to do the same, according to Reuters. During the annual JPMorgan Healthcare Conference, the executive said his company would raise prices just once this year, with the percentage increases not exceeding single digits, the publication noted. Reference Link

ABBV

AbbVie

$61.27

-2.16 (-3.41%)

AGN

Allergan

$216.81

-4.44 (-2.01%)

NVO

Novo Nordisk

$35.61

-0.4 (-1.11%)

  • 11

    Jan

  • 27

    Jan

  • 01

    Feb

  • 21

    Feb

ABBV AbbVie
$61.27

-2.16 (-3.41%)

12/19/16
JEFF
12/19/16
DOWNGRADE
Target $48
JEFF
Underperform
Merck downgraded to Underperform from Hold at Jefferies
Jefferies analyst Jeffrey Holford downgraded Merck (MRK) to Underperform, his firm's sell-rating equivalent. The analyst sees Pharmaceutical sector fundamentals weakening in 2017 amid political overhangs and an adverse macro environment. Potential dual eligible rebate reform is the most significant risk, Holford tells investors in a research note. Specific to Merck, the analyst expects further pressure on Keytruda in 2018, driven by share losses in non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY). Merck screens poorly on many valuation metrics, Holford contends. He lowered his price target for the shares to $48 from $59. The stock closed Friday up 7c to $62.44. The analyst this morning also upgraded both Bristol-Myers Squibb (BMY) and Bayer (BAYRY) to Buy from Hold. His top picks in Pharmaceuticals are AbbVie (ABBV) and Eli Lilly (LLY) for the U.S. and AstraZeneca and Novartis (NVS) in Europe.
12/21/16
PIPR
12/21/16
NO CHANGE
Target $129
PIPR
Overweight
Vertex well in lead but Galapagos a competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says that while Galapagos NV (GLPG) and AbbVie's (ABBV) CFTR potentiator GLPG1837 is " clearly a competitor" following the Phase II SAPHIRA-1 data, Vertex Pharmaceuticals (VRTX) remains "well in the lead." The Phase III KALYDECO plus follow-on VX-661 data is expected in the first half of 2017 while the Phase II triple combination data with VX-440 and VX-152 is expected in the second half of the year, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Vertex with a $129 price target.
01/05/17
JEFF
01/05/17
NO CHANGE
Target $90
JEFF
Buy
Jefferies keeps AbbVie as top global Pharma pick for 2017
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals for 2017. The stock should again outperform as visibility on the timeline for U.S. Humira biosimilars "increases against bearish consensus expectations," Holford tells investors in a research note. He also expects "important advances" on AbbVie's pipeline throughtout the year, and highlights Rova-T, Imbruvica, Venclexta, risankizumab and veliparib. Holford keeps a Buy rating on the shares with a $90 price target.
11/29/16
MAXM
11/29/16
NO CHANGE
Target $6
MAXM
Sell
Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim
Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.
AGN Allergan
$216.81

-4.44 (-2.01%)

01/05/17
WELS
01/05/17
NO CHANGE
WELS
Outperform
Allergan 2017 outlook in-line with estimates, says Wells Fargo
Wells Fargo analyst David Maris says Allergan's preliminary outlook for 2017 today was in-line with his and the current expectations. The analyst notes Allergan's outlook does not include accretion from the recently announced acquisition of LifeCell. Maris keeps an Outperform rating on the shares with a $250-$255 price target range.
12/21/16
BERN
12/21/16
NO CHANGE
BERN
Allergan acquisition has positive aspects, says Bernstein
After Allergan agreed to buy LifeCell, analyst Aaron Gal says that LifeCell seems to "merge well" with Allergan's aesthetics business. The analyst thinks that the acquisition should have "a fair number of synergies," while "LifeCell is another long duration asset that is not protected solely via patent protection." The analyst believes that the cost of the deal is "reasonable." He keeps a $275 price target and an Outperform rating on Allergan.
12/15/16
GSCO
12/15/16
DOWNGRADE
GSCO
Buy
Allergan downgraded to Buy from Conviction Buy at Goldman
12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.
NVO Novo Nordisk
$35.61

-0.4 (-1.11%)

12/06/16
UBSW
12/06/16
UPGRADE
UBSW
Buy
Novo Nordisk upgraded to Buy from Sell at UBS
01/04/17
JPMS
01/04/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novo Nordisk yesterday to Underweight saying consensus expectations are not reflecting the potential for further pricing pressure in the U.S. The analyst has a DKR 225 price target for the shares.
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
01/03/17
JPMS
01/03/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan

TODAY'S FREE FLY STORIES

KFY

Korn/Ferry

$31.27

0.42 (1.36%)

20:27
03/28/17
03/28
20:27
03/28/17
20:27
Conference/Events
Korn/Ferry management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

EEFT

Euronet

$84.38

0.57 (0.68%)

20:25
03/28/17
03/28
20:25
03/28/17
20:25
Conference/Events
Euronet management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PAYX

Paychex

$60.58

-0.31 (-0.51%)

, UNF

UniFirst

$136.05

0.65 (0.48%)

20:25
03/28/17
03/28
20:25
03/28/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PAYX

Paychex

$60.58

-0.31 (-0.51%)

UNF

UniFirst

$136.05

0.65 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 12

    Apr

MGI

MoneyGram

$16.98

0.23 (1.37%)

, EEFT

Euronet

$84.38

0.57 (0.68%)

20:05
03/28/17
03/28
20:05
03/28/17
20:05
Periodicals
Euronet urges U.S. scrutiny of MoneyGram-Ant Financial deal, Reuters says »

Euronet (EEFT) has issued…

MGI

MoneyGram

$16.98

0.23 (1.37%)

EEFT

Euronet

$84.38

0.57 (0.68%)

BABA

Alibaba

$107.80

-0.28 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PPG

PPG

$104.97

1.15 (1.11%)

, AKZOY

AkzoNobel

$28.04

-0.34 (-1.20%)

20:02
03/28/17
03/28
20:02
03/28/17
20:02
Periodicals
AkzoNobel holders push for talks with PPG, FT says »

Investors holding nearly…

PPG

PPG

$104.97

1.15 (1.11%)

AKZOY

AkzoNobel

$28.04

-0.34 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

19:58
03/28/17
03/28
19:58
03/28/17
19:58
Periodicals
Trump to be briefed Thursday on tax overhaul options, Bloomberg says »

President Donald Trump…

F

Ford

$11.65

0.19 (1.66%)

19:45
03/28/17
03/28
19:45
03/28/17
19:45
Conference/Events
Ford management to meet with JPMorgan »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 03

    Apr

  • 27

    Apr

VZ

Verizon

$49.30

0.16 (0.33%)

, CMCSA

Comcast

$37.09

-0.02 (-0.05%)

19:26
03/28/17
03/28
19:26
03/28/17
19:26
Hot Stocks
House joins Senate in passing roll-back of ISP data privacy rules »

Resolution S.J. 34 has…

VZ

Verizon

$49.30

0.16 (0.33%)

CMCSA

Comcast

$37.09

-0.02 (-0.05%)

CMCSK

Comcast

T

AT&T

$41.56

0.07 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 09

    May

TSLA

Tesla

$277.45

7.23 (2.68%)

19:09
03/28/17
03/28
19:09
03/28/17
19:09
Periodicals
Tesla allegedly in Autopilot mode bumps police motorcycle, azcentral says »

A Tesla Model X had a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

TRP

TransCanada

$46.57

-0.07 (-0.15%)

19:05
03/28/17
03/28
19:05
03/28/17
19:05
Periodicals
TransCanada COO Alex Pourbaix to retire in May, Reuters reports »

TransCanada COO Alex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.05

0.36 (0.88%)

19:03
03/28/17
03/28
19:03
03/28/17
19:03
Periodicals
HSBC weighs raising as much as $1B for private credit fund, Bloomberg says »

HSBC's asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Apr

AMZN

Amazon.com

$856.00

9.18 (1.08%)

, EBAY

eBay

$33.53

0.1 (0.30%)

18:55
03/28/17
03/28
18:55
03/28/17
18:55
Hot Stocks
Barclays initiates key Internet names, sets $1,120 target on Amazon »

Barclays initiated…

AMZN

Amazon.com

$856.00

9.18 (1.08%)

EBAY

eBay

$33.53

0.1 (0.30%)

MELI

MercadoLibre

$211.51

-0.06 (-0.03%)

GOOG

Alphabet

$820.92

1.41 (0.17%)

GOOGL

Alphabet Class A

$840.63

2.12 (0.25%)

FB

Facebook

$141.76

1.44 (1.03%)

SNAP

Snap

$22.21

-1.62 (-6.80%)

TWTR

Twitter

$14.94

-0.05 (-0.33%)

GRPN

Groupon

$3.96

0.01 (0.25%)

GDDY

GoDaddy

$36.30

-0.16 (-0.44%)

SHOP

Shopify

$72.37

1.97 (2.80%)

WIX

Wix.com

$66.30

0.15 (0.23%)

WEB

Web.com

$19.30

0.15 (0.78%)

TCEHY

Tencent

$29.49

0.42 (1.44%)

BABA

Alibaba

$107.80

-0.28 (-0.26%)

BIDU

Baidu

$169.79

0.86 (0.51%)

WB

Weibo

$51.61

0.72 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 30

    Mar

  • 18

    Apr

  • 02

    May

  • 16

    May

  • 22

    May

  • 24

    May

VRTX

Vertex

$89.67

-1.13 (-1.24%)

18:46
03/28/17
03/28
18:46
03/28/17
18:46
Hot Stocks
Vertex up 21% after two cystic fibrosis studies show significant improvements »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.65

0.19 (1.66%)

18:46
03/28/17
03/28
18:46
03/28/17
18:46
Hot Stocks
Ford executive chairman acquires 171,379 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 03

    Apr

  • 27

    Apr

RTTR

Ritter Pharmaceuticals

$1.95

-0.01 (-0.51%)

18:35
03/28/17
03/28
18:35
03/28/17
18:35
Hot Stocks
Ritter Pharmaceuticals: RP-G28 shows 'clinically meaningful benefit' in study »

Ritter Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$380.63

5.63 (1.50%)

18:31
03/28/17
03/28
18:31
03/28/17
18:31
Hot Stocks
BlackRock to reposition equity investment platform »

BlackRock is positioning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 12

    Apr

VRTX

Vertex

$89.67

-1.13 (-1.24%)

18:26
03/28/17
03/28
18:26
03/28/17
18:26
Hot Stocks
Vertex says two cystic fibrosis studies show significant improvements »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$54.70

0.55 (1.02%)

, VIAV

Viavi

$10.83

-0.06 (-0.55%)

18:04
03/28/17
03/28
18:04
03/28/17
18:04
Hot Stocks
AlphaOne's Dan Niles says Lumentum and Viavi are 'under the radar stocks' »

AlphaOne's Dan Niles…

LITE

Lumentum

$54.70

0.55 (1.02%)

VIAV

Viavi

$10.83

-0.06 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$26.70

0.2 (0.75%)

18:01
03/28/17
03/28
18:01
03/28/17
18:01
Hot Stocks
HomeStreet CFO Bartels to leave company effective April 23 »

HomeStreet, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CKH

Seacor

$67.35

1.83 (2.79%)

18:00
03/28/17
03/28
18:00
03/28/17
18:00
Earnings
Seacor reports Q4 EPS ($3.36), may not compare with consensus (41c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTX

Pernix Therapeutics

$4.06

-0.11 (-2.64%)

, GSK

GlaxoSmithKline

$42.41

-0.28 (-0.66%)

17:59
03/28/17
03/28
17:59
03/28/17
17:59
Hot Stocks
Pernix says continues to assess various alternatives, including M&A »

"We were pleased to…

PTX

Pernix Therapeutics

$4.06

-0.11 (-2.64%)

GSK

GlaxoSmithKline

$42.41

-0.28 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 06

    Jun

CSC

CSC

$69.07

1.02 (1.50%)

, SWN

Southwestern Energy

$7.89

0.19 (2.47%)

17:57
03/28/17
03/28
17:57
03/28/17
17:57
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P 500 indices »

S&P MidCap 400…

CSC

CSC

$69.07

1.02 (1.50%)

SWN

Southwestern Energy

$7.89

0.19 (2.47%)

HPE

HP Enterprise

$23.01

0.29 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

GM

General Motors

$35.56

0.85 (2.45%)

17:52
03/28/17
03/28
17:52
03/28/17
17:52
Earnings
General Motors backs FY17 EPS view $6.00-$6.50, consensus $6.13 »

The company continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$43.39

0.75 (1.76%)

17:47
03/28/17
03/28
17:47
03/28/17
17:47
Hot Stocks
Continental Resources CEO acquires 41,998 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNET

RigNet

$19.70

-0.2 (-1.01%)

17:39
03/28/17
03/28
17:39
03/28/17
17:39
Hot Stocks
RigNet to provide 4G broadband in Gulf of Mexico deep waters »

RigNet continues its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.